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strated that Mus81-Eme1 could cleave 
Holliday junctions in a purified system. 
Mutants lacking this enzyme had a 
profound meiotic crossover defect 
that could be rescued by expression 
of a bacterial Holliday junction cleaving 
enzyme. Cromie et al. (2006) now show 
that mus81 mutants accumulate Hol-
liday junctions. Combined with earlier 
observations in budding yeast (de los 
Santos et al., 2003), the fission yeast 
studies suggest that not only do the 
predominant DNA intermediates dif-
fer between species, but the enzymes 
most important for resolving those 
intermediates may differ as well.
Differences in the recombination 
mechanisms between fission and bud-
ding yeast argue against a reductionist 
approach to describing the mecha-
nism, even within a single organism. 
Indeed, a number of studies indicate 
that not all recombination occurs via 
the canonical double-strand break 
repair mechanism, even in budding 
yeast (Merker et al., 2003; Allers and 
Lichten, 2001 and references therein). 
Of particular note is work suggesting 
that most noncrossover recombinants 
form by a mechanism that does not 
include a Holliday junction intermediate 
(Figure 1C) (Allers and Lichten, 2001).
Thus, it appears that individual mei-
otic recombination events proceed via 
different mechanisms within an organ-
ism and that the prevalent mechanism 
can differ between organisms. What 
controls progression on one pathway 
versus another? Does pathway preva-
lence vary from one locus to the next, 
and, if so, why? Do different pathways 
contribute distinct biological or evolu-
tionary functions? Can distinguishing 
features of the various pathways give 
us clues about mechanisms of regu-
lation? For example, are double Hol-
liday junctions essential for crossover 
control? Answering these questions 
requires development of better assays 
for diagnostic features of each pathway 
at a given locus as well as examination 
of additional loci in each organism. 
Finally, the new study emphasizes the 
need to characterize recombination 
intermediates in beasts other than 
yeasts.
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The initial factors that trigger the autoimmune response against pancreatic islets in the 
nonobese diabetic (NOD) mouse are still unknown. In this issue of Cell, Razavi et al. (2006) 
propose that a defect in a subset of sensory neurons innervating the pancreas plays a 
major role in initiating the chain of events that will lead to local inflammation, islet destruc-
tion, and autoimmune diabetes.Type 1 diabetes in humans is an 
autoimmune disease in which T cells 
target pancreatic islets of Langer-
hans, leading to the progressive destruction of the insulin-produc-
ing β cells. The nonobese diabetic 
(NOD) mouse spontaneously devel-
ops an autoimmune diabetic disorder Cell 127, Deceresembling human type 1 diabetes 
(reviewed in Anderson and Blue-
stone, 2005). Although both genetic 
and environmental factors contribute mber 15, 2006 ©2006 Elsevier Inc. 1097
to the development of autoim-
mune diabetes, the precise eti-
ology and the initiating factors 
that trigger the autoimmune 
response against pancreatic 
islets are still unknown. In 
this issue, Razavi et al. (2006) 
propose that a defect in sen-
sory neurons innervating the 
pancreas contribute to insulin 
resistance and β cell stress in 
NOD mice by initiating local 
inflammation and an autoim-
mune attack on pancreatic 
islets. These results suggest 
a clear link between autoim-
munity, inflammation, and the 
nervous system. However, is 
the link between the nervous 
system and autoimmunity an 
epiphenomenon, or is there a 
direct link between autoanti-
genic determinants shared by 
these intertwined tissues?
Pancreatic islets are inner-
vated by a network of primary 
sensory afferent neurons, a 
subset of which expresses 
the capsaicin receptor TRPV1 
(transient receptor poten-
tial vanilloid-1). Razavi et al. 
(2006) describe two muta-
tions in conserved regions of 
the trpv1 gene in NOD mice 
and propose trpv1 as a can-
didate gene for the diabetes 
susceptibility locus Idd4.1 on 
chromosome 11. TRPV1 poly-
morphism in NOD mice was 
associated with functional 
defects in neurons express-
ing TRPV1, including reduced 
secretion of substance P from pan-
creatic nerve terminals. Importantly, 
restoration of this function in congenic 
NOD mice expressing the B6 TRPV1 
allele or by local administration of 
substance P led to reduced autore-
active T cell proliferation, islet infiltra-
tion, and diabetes. Thus, the authors 
suggest that a molecular defect in the 
pancreatic innervation system could 
dramatically affect autoimmune dia-
betes. However, previous studies 
have shown that the Idd4 locus does 
not provide complete protection from 
insulitis and diabetes, suggesting 
that the neuronal defect identified by 
the authors does not fully account for 
the initiation of the autoimmune proc-
ess in NOD mice.
The multiple interactions between 
neuronal and endocrine functions led 
to the concept of an integrated neu-
roendocrine system. Intriguingly, the 
demonstration that insulin-producing 
cells found in the brain of the fruit fly 
Drosophila are functionally analogous 
to pancreatic islet β cells led Rulifson 
et al. (2002) to hypothesize the exist-
ence of a common ancestral insu-
lin-producing organ of neural origin. 
The Razavi et al. (2006) study raises 
the possibility that signals delivered 
by the nervous system can 
alter inflammation and insu-
lin resistance and thus “indi-
rectly” affect the development 
of the autoimmunity. However, 
an equally plausible possibility 
is that an autoimmune com-
ponent targeting the nervous 
system directly influences the 
development of autoreactive 
responses against pancreatic 
islets. A high percentage of 
diabetic individuals in Sardinia 
and Canada have multiple 
sclerosis—an autoimmune T 
cell-mediated demyelinating 
process. Furthermore, Dosch 
and colleagues reported T cell 
responses and autoantibodies 
directed at neural cell antigens 
expressed in the central nerv-
ous system or in the peripheral 
nervous system in patients 
with type 1 diabetes (Winer et 
al., 2001; Winer et al., 2003). In 
fact, many proteins thought to 
play a role in type 1 diabetes 
have an expression pattern 
limited to the pancreas and 
the nervous system. Finally, 
autoimmune responses tar-
geting the nervous system 
have been described in the 
NOD mouse. Blocking the 
costimulatory CD28/B7-2 or 
IL-2 pathways in NOD mice 
resulted in the development 
of an autoimmune peripheral 
neuropathy (Salomon et al., 
2001; Setoguchi et al., 2005). 
In addition, T cell responses 
and autoantibodies directed 
at peri-islet Schwann cells and other 
neural structures in the pancreas were 
found in the NOD mouse. Moreover, 
this autoimmune response targeted 
neural antigens shared with islets 
such as glutamic acid decarboxylase 
(GAD65) as well as Schwann cell pro-
teins such as S100β and glial fibril-
lary acidic protein (GFAP) (Winer et 
al., 2001; Winer et al., 2003). Finally, 
Dosch and colleagues have argued 
that responses against neural ele-
ments play an important role in “initi-
ating” autoreactive responses against 
islets. Winer et al. (2003) showed that 
the insulitis that precedes overt clini-
figure 1. Linking Autoimmune Diabetes and the 
nervous system
In normal mice (not shown), a feedback loop involving islet β 
cells and sensory neurons expressing TRPV1 maintains bal-
anced levels of insulin and substance P. In NOD mice, insulin 
secretion by islet β cells fails to properly stimulate the sensory 
neurons expressing TRPV1 to release neuropeptides due to 
the presence of a hypofunctional polymorphism in the trpv1 
gene. Suboptimal local levels of neuropeptides lead to insulin 
resistance and β cell stress as well as a local proinflammatory 
milieu, while physiological cell death of neurons and islet β 
cells leads to the presentation of auto-antigens by profession-
al antigen-presenting cells (APCs) in draining lymph nodes. In-
filtration of Schwann cell and islet-specific T cells is sustained 
by the local proinflammatory milieu resulting from defective 
TRPV1 signals in sensory neurons.1098 Cell 127, December 15, 2006 ©2006 Elsevier Inc.
cal diabetes may be, in part, directed 
against immature Schwann cells sur-
rounding pancreatic islets. Further-
more, T cell lines specific for GFAP 
promote insulitis, whereas antigen-
based therapy inhibits diabetes. 
Dosch and colleagues now extend 
their model to propose that defects in 
TRPV1+ neuron function, particularly 
the reduced release of substance P, 
are directly linked to the mild hyperin-
sulinemia and insulin resistance that 
have been previously described in 
young NOD mice (reviewed in Homo-
Delarche, 2004) and lead to β cell 
stress. Surprisingly, the removal of 
neurons expressing TRPV1 by neo-
natal capsaicin treatment resulted 
in a similar outcome on anti-islet 
autoimmunity as restoration of their 
function. Razavi et al. (2006) explain 
this paradox by a model in which only 
subnormal local levels of neuropep-
tides are pathogenic and lead to β cell 
stress and inflammation. Although 
neuropeptides can have opposite 
physiological effects at different con-
centrations, it will remain to be con-
firmed whether complete elimination 
of neurons expressing TRPV1 affects 
diabetes through distinct pathways, 
such as antigen removal or increased 
regulatory T cells as shown by Razavi 
et al. (2006).
The authors propose that together 
with reduced local levels of sub-
stance P, which has anti-inflamma-
tory effects, β cell stress contributes 
to the recruitment of mononuclear 
cells that marks the beginning of the 
autoimmune process against NOD 
islets (Razavi et al., 2006). Indeed, 
insulin resistance was abrogated in 
NOD-B6-Idd4 congenic mice or after 
local administration of substance P 
in NOD mice. This mechanism may 
not be limited to substance P as the 
transgenic expression in pancreatic 
islets of calcitonin gene-related pep-
tide (CGRP), another neuropeptide 
that has immunosuppressive proper-ties and is released by sensory neu-
rons, resulted in reduced diabetes 
incidence in NOD mice (Khachatryan 
et al., 1997). From a kinetic stand-
point, it is remarkable that physiolog-
ical cell death of both neurons and 
islet β cells occurs shortly after birth 
in all strains of mice and may lead to 
the presentation of autoantigens by 
professional antigen-presenting cells 
in draining lymph nodes. Thus, the 
precise timing of antigen release and 
presentation and of local inflammation 
secondary to neuronal defects may 
determine whether initial autoreactive 
T cell responses are directed against 
islet or neural antigens. Importantly, 
the defective feedback loop between 
neurons expressing TRPV1 and β 
cells was observed in immunodefi-
cient NOD (NOD-SCID) mice as well, 
supporting the hypothesis that it may 
initiate local inflammation rather than 
be a consequence of it. Furthermore, 
there are patients with a complex 
form of diabetes with unexplained 
combinations of syndromes from 
types 1 (autoimmunity) and 2 (insu-
lin resistance). These are sometimes 
referred to as “type 1-1/2” and have 
some characteristics consistent with 
the syndromes described by Razavi 
et al. (2006). Interestingly, abnormal β 
cell function has also been described 
in NOD mice and was believed to be 
secondary to high levels of inflam-
matory mediators during the autoim-
mune process. However, recent 
data by Chaparro et al. (2006) iden-
tify intrinsic alterations of pancreas 
physiology in the absence of autoim-
mune responses in NOD-SCID mice, 
including ER protein stress and insulin 
resistance. The findings by Razavi et 
al. (2006) possibly link these param-
eters commonly associated with 
type 2 diabetes to abnormal sensory 
neuron function in NOD mice. Con-
versely, insulin resistance and β cell 
stress have been described in mouse 
models that do not develop autoim-Cell 127, Decemune diabetes. Thus, the findings 
presented by Dosch and colleagues 
ought to be put in the context of other 
defects in central and peripheral tol-
erance afflicting the NOD mouse to 
be included in a general model (Fig-
ure 1) integrating neuroendocrine 
and immunological defects that lead 
to autoimmune diabetes. Finally, this 
report once again raises the question 
of the tissue specificity of autoimmu-
nity in mice and humans. Particularly, 
additional studies will be needed to 
reconcile the fact that the principal 
target of autoimmunity remains the 
pancreatic islet in unmanipulated 
NOD mice despite strong evidence of 
the implication of the nervous system 
in this process.
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